MX2022013029A - Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos. - Google Patents

Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos.

Info

Publication number
MX2022013029A
MX2022013029A MX2022013029A MX2022013029A MX2022013029A MX 2022013029 A MX2022013029 A MX 2022013029A MX 2022013029 A MX2022013029 A MX 2022013029A MX 2022013029 A MX2022013029 A MX 2022013029A MX 2022013029 A MX2022013029 A MX 2022013029A
Authority
MX
Mexico
Prior art keywords
methods
compositions
neuropsychiatric disorders
treating neuropsychiatric
treating
Prior art date
Application number
MX2022013029A
Other languages
English (en)
Inventor
Alon Seifan
Original Assignee
Honeybrains Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Honeybrains Llc filed Critical Honeybrains Llc
Publication of MX2022013029A publication Critical patent/MX2022013029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Como se describe a continuación, la presente invención presenta composiciones y métodos para tratar trastornos de la salud mental y/o del comportamiento y sus síntomas asociados.
MX2022013029A 2020-04-17 2021-04-16 Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos. MX2022013029A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011932P 2020-04-17 2020-04-17
US202063111156P 2020-11-09 2020-11-09
PCT/US2021/027641 WO2021211944A1 (en) 2020-04-17 2021-04-16 Compositions and methods for treating neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
MX2022013029A true MX2022013029A (es) 2023-01-16

Family

ID=78084126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013029A MX2022013029A (es) 2020-04-17 2021-04-16 Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos.

Country Status (11)

Country Link
US (4) US20230218583A1 (es)
EP (1) EP4136103A4 (es)
JP (1) JP2023522206A (es)
KR (1) KR20230005229A (es)
CN (1) CN116134048A (es)
AU (1) AU2021255701A1 (es)
BR (1) BR112022021011A2 (es)
CA (1) CA3180330A1 (es)
IL (1) IL297333A (es)
MX (1) MX2022013029A (es)
WO (1) WO2021211944A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230005229A (ko) * 2020-04-17 2023-01-09 허니브레인즈, 엘엘씨 신경정신계 장애를 치료하기 위한 조성물 및 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654372A (en) * 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
US4985256A (en) * 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
EP1870098A3 (en) * 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
US6734215B2 (en) * 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
WO2005037215A2 (en) * 2003-10-14 2005-04-28 Massachusetts Institute Of Technology Compositions and methods for enhancing cognitive function and synaptic plasticity
US20110269717A1 (en) 2006-07-17 2011-11-03 Braincells Inc. Neurogenesis by modulating angiotensin
US8178118B2 (en) * 2007-03-22 2012-05-15 Magceutics, Inc. Magnesium compositions and uses thereof for cognitive function
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
WO2010006103A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Method for enhancing cognition or inhibiting cognitive decline
CN101890165A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 降压组合物及用途
CN102266559A (zh) * 2010-06-01 2011-12-07 王丽燕 包含替米沙坦盐和钙离子拮抗剂的药物组合物
KR101378973B1 (ko) 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
US20150343067A1 (en) 2012-12-27 2015-12-03 Hennig Arzneimittel Gmbh & Co. Kg, Monolithic Dosage Form for the Modified Release of an Active Ingredient Combination
BR112016026950B1 (pt) 2014-05-22 2023-03-07 Alnylam Pharmaceuticals, Inc Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
EP2979691A1 (en) * 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
ES2784398T3 (es) 2015-06-01 2020-09-24 Rugen Holdings Cayman Ltd Compuestos heterocíclicos de 3,3-difluoropiperidina carbamato como antagonistas del receptor de NMDA NR2B
US10626105B2 (en) 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
CN108771657B (zh) 2017-06-22 2020-11-06 四川大学 一种小分子药物原位相变凝胶缓释系统及其制备方法
KR20230005229A (ko) * 2020-04-17 2023-01-09 허니브레인즈, 엘엘씨 신경정신계 장애를 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
US20230218583A1 (en) 2023-07-13
US20230310383A1 (en) 2023-10-05
US11583520B2 (en) 2023-02-21
CN116134048A (zh) 2023-05-16
US20220008396A1 (en) 2022-01-13
IL297333A (en) 2022-12-01
AU2021255701A1 (en) 2022-12-08
US11491142B2 (en) 2022-11-08
EP4136103A1 (en) 2023-02-22
EP4136103A4 (en) 2024-05-15
BR112022021011A2 (pt) 2022-12-27
US20220023264A1 (en) 2022-01-27
WO2021211944A1 (en) 2021-10-21
CA3180330A1 (en) 2021-10-21
KR20230005229A (ko) 2023-01-09
JP2023522206A (ja) 2023-05-29

Similar Documents

Publication Publication Date Title
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
BR112019003172A2 (pt) frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento
PH12019500196A1 (en) Compounds and compositions and uses thereof
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
MX2020006385A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia.
MX2020002762A (es) Composiciones y métodos para tratar una lesión cerebral.
WO2015143447A3 (en) Methods for treating neurological disorders
MA48939B1 (fr) Compositions comprenant des souches bactériennes
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
WO2019075456A3 (en) Methods and substances for prevention and treatment of neurodegenerative diseases
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2022013029A (es) Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.